FNAIT-associated perinatal death or severe brain damage in the newborn baby is believed to occur in 1:10000 pregnancies. With 9 million births in the US and the European Union annually there will be around 1,000 cases with severe
FNAIT-related complications in the Us and EU per year.
The PROFNAIT project aims at developing a drug for the prevention of FNAIT. This drug will prevent the majority of these severe events of which many today result in lifelong disabilities or death and major costs to society.
In the PROFNAIT project, Prophylix Pharma collaborates closely with leading Northern European hospitals, blood banks and companies with key expertises in this area. Together we strive to bring this novel treatment to the market to the benefit of babies at risk of developing FNAIT and to the benefit of their mothers and families.